1. Dietary supplements containing ephedra [electronic resource] : health risks and FDA's oversight : statement of Marcia Crosse, Acting Director, Health Care--Public Health and Science Issues, before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives / United States General Accounting Office. Crosse, Marcia [Browse] Washington, D.C. : U.S. General Accounting Office, [2003] Book Online Federal Depository Library Program Documents Bookmark
2. VA health care [microform] : VA's management of drugs on its national formulary : report to the ranking minority member, Committee on Veterans' Affairs, U.S. Senate. Washington, D.C. (441 G St., NW, Rm. LM, Washington, 20548) : U.S. General Accounting Office, [1999] Book, Microform Online Federal Depository Library Program Documents Bookmark
3. Prescription drugs : implications of drug labeling and off-label use : statement of Sarah F. Jagger, Director of Health Services Quality and Public Health Issues, Health, Education, and Human Services Division, before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives / United States General Accounting Office. Jagger, Sarah F. [Browse] Washington, D.C. : The Office ; Gaithersburg, MD (P.O. Box 6015, Gaithersburg 20884-6015) : The Office [distributor, 1996] Book Online Federal Depository Library Program Documents Bookmark
4. Problems in obtaining and enforcing compliance with good manufacturing practices for drugs, Food and Drug Administration, Department of Health, Education and Welfare; report to the Congress by the Comptroller General of the United States. United States. General Accounting Office [Browse] [Washington] 1973. Book Loading...ReCAP - Remote Storage » RS189.U54 Bookmark
5. FDA can further improve its adverse drug reaction reporting system : report to the Secretary of Health and Human Services / by the U.S. General Accounting Office. United States. General Accounting Office [Browse] Washington : The Office, [1982] Book AvailableReCAP - Remote Storage » QV 771 U288f 1982 Bookmark
6. FDA drug approval, a lengthy process that delays the availability of important new drugs : report to the Subcommittee on Science, Research, and Technology, House Committee on Science and Technology / by the Comptroller General of the United States. United States. General Accounting Office [Browse] Washington, D.C. : U.S. General Accounting Office, 1981. Book AvailableReCAP - Remote Storage » QV 771 U588f 1981 Bookmark